• NCBINCBI Logo
  • Skip to main
    content
  • Skip to
    navigation
  • Resources
  • How To
  • About NCBI Accesskeys
My NCBI Sign in to NCBI Sign Out

PMC

US National Library of Medicine

National Institutes of Health
  • Advanced
  • Journal list
  • Help

  • Journal List
  • CMAJ
  • v.183(8); 2011 May 17
  • PMC3091903
Logo of cmaj

CMAJ. 2011 May 17; 183(8): 932.
doi:  [ 10.1503/cmaj.100841 ]
PMCID: PMC3091903
PMID: 21398239

Oral hairy leukoplakia: a clinical indicator of immunosuppression

Alexander Kreuter , MD and Ulrike Wieland , MD
Author information Copyright and License information Disclaimer
From the Department of Dermatology, Venereology and Allergology (Kreuter), Ruhr University, Bochum, Germany; and the Institute of Virology (Wieland), University of Cologne, Cologne, Germany
Correspondence to: Dr. Alexander Kreuter, [email protected]
Copyright © 1995-2011, Canadian Medical Association

A 29-year-old man presented with non-painful white lesions on his tongue that he had recently noticed while brushing his teeth. Testing for oral candidal infection by his general practitioner was negative. The patient was feeling otherwise healthy and had no further complaints. Clinical examination showed bilateral corrugated, adherent plaques located on the dorsal tongue surfaces ( Figure 1 ). Testing for HIV was positive. The patient’s CD4 count was 0.28 (normal 0.3–1.4) × 109/L, and his viral load was 431 000 HIV-1 RNA copies/mL. Ten weeks after the initiation of highly active antiretroviral therapy (HAART), all lesions had completely resolved.

An external file that holds a picture, illustration, etc.
Object name is 1830932f1.jpg

Open in a separate window
Figure 1:

(A) Painless white adherent plaques on the dorsal tongue surfaces of a 29-year-old man. (B) Close-up view of a lesion: the surface of the patch has a corrugated appearance forming prominent folds.

Oral hairy leukoplakia, first described in 1984, is a mucosal disease associated with Epstein–Barr virus infection and almost exclusively occuring in people with immunosupression. It occurs in up to 50% of patients with untreated HIV, particularly those whose CD4 count is less than 0.3 × 109/L. 1 The condition has a clear prognostic value for the subsequent development of AIDS and is classified as a Centers for Disease Control and Prevention category-B clinical marker of HIV disease. 2 Oral hairy leukoplakia has also been described in conjunction with hematologic malignancy and organ and bone marrow transplantation, and in patients receiving systemic steroids. Rarely, it has been reported in the absence of immunosuppression. 3

The pathogenesis of oral hairy leukoplakia is complex and includes an interplay of persistent Epstein–Barr virus replication and virulence, systemic immunosuppression and suppression of the local host immunity. 3 The differential diagnoses include oral candidiasis, lichen planus, tobacco-associated leukoplakia, human papillomavirus–induced oral intraepithelial neoplasia, and oral squamous cell carcinoma. In most instances, oral hairy leukoplakia can be diagnosed clinically and does not require a confirmatory biopsy. It does not require specific treatment and frequently resolves under HAART, if associated with HIV infection. 4

Footnotes

Competing interests: Alexander Kreuter is a board member of Wyeth. Ulrike Wieland has received payment for lectures from Roche and bioMérieux.

This article has been peer reviewed.

References

1. Bravo IM, Correnti M, Escalona L, et al. Prevalence of oral lesions in HIV patients related to CD4 cell count and viral load in a Venezuelan population. Med Oral Patol Oral Cir Bucal 2006; 11:E33–9 [ PubMed ]
2. Centers for Disease Control and Prevention 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR 1992;41:RR-17 [ PubMed ]
3. Piperi E, Omlie J, Koutlas IG, et al. Oral hairy leukoplakia in HIV-negative patients: report of 10 cases. Int J Surg Pathol 2010; 18:177–83 [ PubMed ]
4. Nokta M. Oral manifestations associated with HIV infection. Curr HIV/AIDS Rep 2008;5:5–12 [ PubMed ]

Articles from CMAJ : Canadian Medical Association Journal are provided here courtesy of Canadian Medical Association

Formats:

  • Article
  • |

  • PubReader
  • |

  • ePub (beta)
  • |

  • PDF (84K)
  • |

  • Citation

Share

  • Share on Facebook
    Facebook
  • Share on Twitter
    Twitter
  • Share on Google Plus
    Google+

Support Center
Support Center

External link. Please review our privacy policy .
NLM
NIH
DHHS
USA.gov


National Center for
Biotechnology Information ,
U.S. National Library of Medicine

8600 Rockville Pike, Bethesda
MD, 20894
USA

Policies and Guidelines | Contact

You are currently logged into

POZ Directory –
My Account
or
Log Out

POZ

POZ

© 2018
Smart + Strong .
All Rights Reserved.
Terms of use and Your privacy .
Smart + Strong ®
is a registered trademark of CDM Publishing, LLC.

Advertisement

  • Previous
    Prev
    Mycobacterium Kansasii

  • MAIN MENU
    HIV/AIDS

  • Next
    Pneumocystis Pneumonia (PCP)

Opportunistic Infections

Oral Hairy Leukoplakia (OHL)

Tweet

Share


Twitter

Facebook

Google +

Pinterest

Tumblr

Email




  • Share

  • Print


Oral hairy leukoplakia refers to a white patch that forms in the mouth. These patches usually appear along the sides of the tongue, or on the top and underside of the tongue or along the inside of the cheek. They may appear shaggy or contain a number of tiny folds or ridges.

OHL can look like  thrush , a similar oral condition that occurs in people with HIV. However, thrush usually comes off when it is lightly scraped with a toothbrush, while OHL does not.

OHL is caused by the Epstein-Barr virus (EBV). Most people in the world are infected with EBV, and it usually causes disease as the immune system weakens. OHL rarely causes serious physical problems and does not progress to more serious conditions.

In people living with HIV, OHL can occur at any CD4 count, but it is most common among people with less than 200 CD4s. OHL can also occur in HIV-negative people. More than 1 out of 4 people with HIV will develop OHL at some point during the course of their infection. It is most common among men and smokers.

 

What are the symptoms of OHL?

White, usually painless patches that are shaggy or ridged in appearance can develop on the sides of the tongue. OHL can also cause patches on the top or underside of the tongue or along the inside of the cheek. These may not look shaggy or that they contain ridges or folds.

These patches do not usually cause discomfort and generally do not affect the taste of foods or liquids. In some cases, however, OHL can cause mild pain and may alter a person’s taste buds and sensitivity to food temperatures.

 

How is it diagnosed?

A health provider usually diagnoses OHL simply by looking at the white patch. Using a tongue depressor or toothbrush, the patch can be lightly scraped. If it appears to come off with scraping, the patch is probably thrush. To be sure that it’s OHL, a clinician will send a sample of the patch to a lab to look for the Epstein-Barr virus.

 

How is it treated or prevented?

OHL usually does not require treatment or cause serious symptoms. However, treatment is an option for people who are unhappy with the white patches on their tongues or for those with many lesions who are experiencing discomfort or altered taste because of the patches.

Antiviral medications, taken by mouth, are used to treat OHL. These are usually taken for 1–2 weeks or until the OHL patches have disappeared:

 

Acyclovir (Zovirax): Acyclovir has been used for many years for OHL. It rarely causes side effects. The usual dose is 800 mg taken five times a day for at least a week. Taking lower doses over time can help prevent OHL from coming back for those with a history of frequent recurrences.

Valacyclovir (Valtrex): Valacyclovir is a “pro-drug” of acyclovir and needs to be broken down by the body before its active ingredient—acyclovir—can begin controlling the disease. This allows for higher amounts of acyclovir to stay in the body, which means a lower dose is taken by mouth three times a day. Like acyclovir, valacyclovir rarely causes side effects.

 

Famciclovir (Famvir): Famciclovir is the pill form of a topical cream called penciclovir (Denavir). It is taken three times a day until the patches have disappeared.

Other options include tretinoin (Retin A) and podophyllin resin, two medications that can be applied on the OHL patches. Tretinoin is usually applied two or three times a day until the patches have disappeared. Podophyllin is applied once or twice over a two- to three-week period by a health provider. Another option, especially if the OHL patches are small, is for a health provider to apply liquid nitrogen (cryotherapy) to the affected area or to remove the patches surgically.

There is no sure way to prevent OHL patches from occurring. However, keeping the immune system healthy is the best possible way to prevent OHL. This means keeping viral load low and CD4 cells high using potent HIV treatment and by adopting a healthy lifestyle.

 

Are there any experimental treatments?

At the present time, there are no new medications being developed for the treatment of OHL, given that OHL is not a serious opportunistic infection and medications are available to treat it. However, if you would like to find out if clinical trials of new OHL treatments are being conducted, visit  ClinicalTrials.gov , a site run by the U.S. National Institutes of Health. The site has information about all HIV-related clinical studies in the United States. For more info, you can call their toll-free number at 1-800-HIV-0440 (1-800-448-0440) or email [email protected]

Last Reviewed: October 23, 2018


  • #Oral Hairy Leukoplakia
  • #oral health


  • Previous
    Prev
    Mycobacterium Kansasii

  • MAIN MENU
    HIV/AIDS

  • Next
    Pneumocystis Pneumonia (PCP)


Advertisement

RELATED articles

Poor Oral and Mental Health Are Related in People With HIV

Lawsuit: Dentist Denied Woman Meds Because She Has HIV [VIDEO]

POZ Magazine

HIV Transmission Inconclusive in Oklahoma Dental Patients

POZ Magazine

HIV, Hep Confirmed in Initial Tests of Oklahoma Dental Patients


Hot topics

Forums: Support and discussion

Blogs: The community speaks

POZ Stories: Get inspired

Magazine: Search the archives

HIV: The Basics

Recursos de VIH/SIDA en Español

AIDS Is Everyday

Ask POZ


Newsletter

Email updates from POZ

Sign up

Advertisement

POZ Personals

  • Trending
  • Shared
  • COMMENTS
  • Freddie Mercury Bio Links the Rock Star to AIDS “Patient Zero”
  • Trump Wants to Restrict Access to HIV Meds for People on Medicare
  • Repeat After Me: You Can’t Get HIV From Food!
  • “I’m on the Pill” PrEP Ads Begin Airing on National TV
  • The Road Ahead for HIV Cure Research
  • Trump Wants to Restrict Access to HIV Meds for People on Medicare
  • Freddie Mercury Bio Links the Rock Star to AIDS “Patient Zero”
  • Undetectable Meant Zero HIV Transmissions After 89,000 Condomless Sex Acts
  • CDC: “Effectively No Risk” of Sexual HIV Transmission if Undetectable
  • The Unintended Consequences of AIDS Survival
  • Trump Wants to Restrict Access to HIV Meds for People on Medicare
  • How to Cope When You’re Looking for Love but Finding HIV Stigma Instead
  • HIV-Negative Men Are Still Choosing Stigma Over Science
  • The “Absolute Charade” of Pence’s World AIDS Day Address [VIDEO]
  • Real Stories of HIV Stigma and Its (Often Surprising) Outcomes

Advertisement

Current issue

Alt text

POZ December 2018

  • The POZ 100: Celebrating People 50 And Over
  • Strong & Healthy
  • Community Relations
View more

Trending tags

  • #HIV
  • #Prevention
  • #Global
  • #Advocacy
  • #PrEP
  • #AIDS
  • #MSM
  • #gay
  • #hepatitis C
  • #antiretrovirals
  • #Criminalization
  • #World AIDS Day
  • #Celebrities
  • #Women
  • #stigma
  • #Cure
  • #New York City
  • #transmission
  • #treatment

POZ Poll

POZ Poll: Have you ever volunteered at an AIDS fundraiser or service organization?

Thank you for your participation!

This is poll is currently not showing results, please visit our poll listing for current or past polls.

Yes.

63%

No.

37%

View Archives

POZ Survey

Time After Time

Service Directory

POZ Blogs

  • Looking Back on “Philadelphia” and How It Changed My Life
  • Full Disclosure: HIV Shame at the Dentist
  • The 2019 HIV League Scholarship Application Is Now Open!
  • 20 Years
  • 15 Years
  • 10 Years

POZ December 1998

  • The Age of Ignorance
  • Reboot Your System
  • POZ Annual Givers Guide
View more

POZ December 2003

  • Born Again
  • Knowing When to Stop
  • The Divine Miss Em
View more

POZ December 2008

  • Gimme Shelter
  • The POZ and AIDSmeds Drug Chart
  • A Porn Star is Reborn
View more

POZ Personals

POZ on Facebook

POZ

POZ on Twitter

Tweets by pozmagazine

POZ on Instagram

@pozmagazine

Social Media


Facebook

Twitter

Tumblr

Instagram

Pinterest

Google+

YouTube

Related Sites

  • HEP
  • REAL HEALTH
  • CANCER HEALTH
  • SMART + STRONG

Newsletter subscription

Thank you!
Please watch for email(s) from us to confirm your subscription to your selected newsletter(s).
Please enter a valid email address.
The Captcha is required.
Please select Newsletter option.

Stay Logged In?

You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.


You Have Been Logged Out

Click here to log back in.